Treatment of cancer with naltrexone
US9895438B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 12, 2014 |
| Grant date | Feb 20, 2018 |
| Priority date | — |
| Expiry date | May 12, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/585
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel therapeutic applications of low dose naltrexone (LDN). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of Toll-like receptor 9 (TLR9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized. Chronic inflammation and TLR9 overexpression are characteristics of a number of disorders, including certain cancers. Accordingly, the present invention provides novel uses of naltrexone in the treatment of a subject having a disorder characterized by TLR9 overexpression and/or overactivity of TLR9-mediated signalling. The present invention also provides novel uses of naltrexone in the supportive care of subject having a tumor/cancer, and methods of treating and providing supportive care to a subject, comprising the administration of naltrexone.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.